A Synthetic Agonist to Vasoactive Intestinal Peptide Receptor-2 Induces Regulatory T Cell Neuroprotective Activities in Models of Parkinson’s Disease

R. Lee Mosley, Yaman Lu, Katherine E. Olson, Jatin Machhi, Wenhui Yan, Krista L. Namminga, Jenell R. Smith, Scott J. Shandler, Howard E. Gendelman

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

A paradigm shift has emerged in Parkinson’s disease (PD) highlighting the prominent role of CD4+ Tregs in pathogenesis and treatment. Bench to bedside research, conducted by others and our own laboratories, advanced a neuroprotective role for Tregs making pharmacologic transformation of immediate need. Herein, a vasoactive intestinal peptide receptor-2 (VIPR2) peptide agonist, LBT-3627, was developed as a neuroprotectant for PD-associated dopaminergic neurodegeneration. Employing both 6-hydroxydopamine (6-OHDA) and α-synuclein (α-Syn) overexpression models in rats, the sequential administration of LBT-3627 increased Treg activity without altering cell numbers both in naïve animals and during progressive nigrostriatal degeneration. LBT-3627 administration was linked to reductions of inflammatory microglia, increased survival of dopaminergic neurons, and improved striatal densities. While α-Syn overexpression resulted in reduced Treg activity, LBT-3627 rescued these functional deficits. This occurred in a dose-dependent manner closely mimicking neuroprotection. Taken together, these data provide the basis for the use of VIPR2 agonists as potent therapeutic immune modulating agents to restore Treg activity, attenuate neuroinflammation, and interdict dopaminergic neurodegeneration in PD. The data underscore an important role of immunity in PD pathogenesis.

Original languageEnglish (US)
Article number421
JournalFrontiers in Cellular Neuroscience
Volume13
DOIs
StatePublished - Sep 18 2019

Fingerprint

Receptors, Vasoactive Intestinal Peptide, Type II
Regulatory T-Lymphocytes
Parkinson Disease
Oxidopamine
Synucleins
Corpus Striatum
Dopaminergic Neurons
Microglia
Neuroprotective Agents
Immunity
Cell Count
Peptides
LBT-3627
Research

Keywords

  • 6-hydroxydopamine
  • Parkinson’s disease
  • agonist
  • alpha-synuclein
  • microglia
  • neurodegeneration
  • regulatory T cells
  • vasoactive intestinal peptide

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience

Cite this

A Synthetic Agonist to Vasoactive Intestinal Peptide Receptor-2 Induces Regulatory T Cell Neuroprotective Activities in Models of Parkinson’s Disease. / Mosley, R. Lee; Lu, Yaman; Olson, Katherine E.; Machhi, Jatin; Yan, Wenhui; Namminga, Krista L.; Smith, Jenell R.; Shandler, Scott J.; Gendelman, Howard E.

In: Frontiers in Cellular Neuroscience, Vol. 13, 421, 18.09.2019.

Research output: Contribution to journalArticle

Mosley, R. Lee ; Lu, Yaman ; Olson, Katherine E. ; Machhi, Jatin ; Yan, Wenhui ; Namminga, Krista L. ; Smith, Jenell R. ; Shandler, Scott J. ; Gendelman, Howard E. / A Synthetic Agonist to Vasoactive Intestinal Peptide Receptor-2 Induces Regulatory T Cell Neuroprotective Activities in Models of Parkinson’s Disease. In: Frontiers in Cellular Neuroscience. 2019 ; Vol. 13.
@article{7410a070dce54ebeac2bd10b4d1562f9,
title = "A Synthetic Agonist to Vasoactive Intestinal Peptide Receptor-2 Induces Regulatory T Cell Neuroprotective Activities in Models of Parkinson’s Disease",
abstract = "A paradigm shift has emerged in Parkinson’s disease (PD) highlighting the prominent role of CD4+ Tregs in pathogenesis and treatment. Bench to bedside research, conducted by others and our own laboratories, advanced a neuroprotective role for Tregs making pharmacologic transformation of immediate need. Herein, a vasoactive intestinal peptide receptor-2 (VIPR2) peptide agonist, LBT-3627, was developed as a neuroprotectant for PD-associated dopaminergic neurodegeneration. Employing both 6-hydroxydopamine (6-OHDA) and α-synuclein (α-Syn) overexpression models in rats, the sequential administration of LBT-3627 increased Treg activity without altering cell numbers both in na{\"i}ve animals and during progressive nigrostriatal degeneration. LBT-3627 administration was linked to reductions of inflammatory microglia, increased survival of dopaminergic neurons, and improved striatal densities. While α-Syn overexpression resulted in reduced Treg activity, LBT-3627 rescued these functional deficits. This occurred in a dose-dependent manner closely mimicking neuroprotection. Taken together, these data provide the basis for the use of VIPR2 agonists as potent therapeutic immune modulating agents to restore Treg activity, attenuate neuroinflammation, and interdict dopaminergic neurodegeneration in PD. The data underscore an important role of immunity in PD pathogenesis.",
keywords = "6-hydroxydopamine, Parkinson’s disease, agonist, alpha-synuclein, microglia, neurodegeneration, regulatory T cells, vasoactive intestinal peptide",
author = "Mosley, {R. Lee} and Yaman Lu and Olson, {Katherine E.} and Jatin Machhi and Wenhui Yan and Namminga, {Krista L.} and Smith, {Jenell R.} and Shandler, {Scott J.} and Gendelman, {Howard E.}",
year = "2019",
month = "9",
day = "18",
doi = "10.3389/fncel.2019.00421",
language = "English (US)",
volume = "13",
journal = "Frontiers in Cellular Neuroscience",
issn = "1662-5102",
publisher = "Frontiers Research Foundation",

}

TY - JOUR

T1 - A Synthetic Agonist to Vasoactive Intestinal Peptide Receptor-2 Induces Regulatory T Cell Neuroprotective Activities in Models of Parkinson’s Disease

AU - Mosley, R. Lee

AU - Lu, Yaman

AU - Olson, Katherine E.

AU - Machhi, Jatin

AU - Yan, Wenhui

AU - Namminga, Krista L.

AU - Smith, Jenell R.

AU - Shandler, Scott J.

AU - Gendelman, Howard E.

PY - 2019/9/18

Y1 - 2019/9/18

N2 - A paradigm shift has emerged in Parkinson’s disease (PD) highlighting the prominent role of CD4+ Tregs in pathogenesis and treatment. Bench to bedside research, conducted by others and our own laboratories, advanced a neuroprotective role for Tregs making pharmacologic transformation of immediate need. Herein, a vasoactive intestinal peptide receptor-2 (VIPR2) peptide agonist, LBT-3627, was developed as a neuroprotectant for PD-associated dopaminergic neurodegeneration. Employing both 6-hydroxydopamine (6-OHDA) and α-synuclein (α-Syn) overexpression models in rats, the sequential administration of LBT-3627 increased Treg activity without altering cell numbers both in naïve animals and during progressive nigrostriatal degeneration. LBT-3627 administration was linked to reductions of inflammatory microglia, increased survival of dopaminergic neurons, and improved striatal densities. While α-Syn overexpression resulted in reduced Treg activity, LBT-3627 rescued these functional deficits. This occurred in a dose-dependent manner closely mimicking neuroprotection. Taken together, these data provide the basis for the use of VIPR2 agonists as potent therapeutic immune modulating agents to restore Treg activity, attenuate neuroinflammation, and interdict dopaminergic neurodegeneration in PD. The data underscore an important role of immunity in PD pathogenesis.

AB - A paradigm shift has emerged in Parkinson’s disease (PD) highlighting the prominent role of CD4+ Tregs in pathogenesis and treatment. Bench to bedside research, conducted by others and our own laboratories, advanced a neuroprotective role for Tregs making pharmacologic transformation of immediate need. Herein, a vasoactive intestinal peptide receptor-2 (VIPR2) peptide agonist, LBT-3627, was developed as a neuroprotectant for PD-associated dopaminergic neurodegeneration. Employing both 6-hydroxydopamine (6-OHDA) and α-synuclein (α-Syn) overexpression models in rats, the sequential administration of LBT-3627 increased Treg activity without altering cell numbers both in naïve animals and during progressive nigrostriatal degeneration. LBT-3627 administration was linked to reductions of inflammatory microglia, increased survival of dopaminergic neurons, and improved striatal densities. While α-Syn overexpression resulted in reduced Treg activity, LBT-3627 rescued these functional deficits. This occurred in a dose-dependent manner closely mimicking neuroprotection. Taken together, these data provide the basis for the use of VIPR2 agonists as potent therapeutic immune modulating agents to restore Treg activity, attenuate neuroinflammation, and interdict dopaminergic neurodegeneration in PD. The data underscore an important role of immunity in PD pathogenesis.

KW - 6-hydroxydopamine

KW - Parkinson’s disease

KW - agonist

KW - alpha-synuclein

KW - microglia

KW - neurodegeneration

KW - regulatory T cells

KW - vasoactive intestinal peptide

UR - http://www.scopus.com/inward/record.url?scp=85072844174&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072844174&partnerID=8YFLogxK

U2 - 10.3389/fncel.2019.00421

DO - 10.3389/fncel.2019.00421

M3 - Article

C2 - 31619964

AN - SCOPUS:85072844174

VL - 13

JO - Frontiers in Cellular Neuroscience

JF - Frontiers in Cellular Neuroscience

SN - 1662-5102

M1 - 421

ER -